With roughly 5,500 individuals remaining in the wild, the black rhino population is critically endangered. To help save these iconic African giants, at risk for […]

The post A Planet in Peril: Q&A with Suzan Murray of the Smithsonian Global Health Program appeared first on Smithsonian Insider.

In the past 50 years, the amount of water in the open ocean with zero oxygen has increased more than fourfold. In coastal water bodies, […]

The post Earth’s oceans are losing their breath. Here’s the global scope appeared first on Smithsonian Insider.

Tidal Freshwater Wetlands focuses on wetlands found in North America and Europe near the mouths of rivers that flow into estuaries like the Chesapeake Bay.

The post New book reveals tidal freshwater wetlands are on frontlines of global change appeared first on Smithsonian Insider.

In the battle against invasive species, giant commercial ships are on the front lines. But even when they follow the rules, one of their best […]

The post Battle against invasive marine species comes up short as global shipping surges appeared first on Smithsonian Insider.

The Encyclopedia of Life is an unprecedented global effort to document all 1.8 million named species of animals, plants and other forms of life on Earth. For the first time in the history of the planet, scientists, students, and citizens will have multi-media access to all known living species, even those that have just been discovered. The Field Museum of Natural History, Harvard University, Marine Biological Laboratory, Smithsonian Institution, and Biodiversity Heritage Library joined together to initiate the project, bringing together species and software experts from across the world. Lean more at www.eol.org

The post The Encyclopedia of Life is a global effort to document all 1.8 million named species of animals, plants and other life forms on Earth appeared first on Smithsonian Insider.

Nearly 60 million years ago rainforests prospered at temperatures that were 3-5 degrees higher and at atmospheric carbon dioxide levels 2.5 times today’s levels.

The post Plant diversity in tropical forests increased during ancient global warming event appeared first on Smithsonian Insider.

The post Smithsonian paleobotanist Scott Wing discusses ancient global warming & what it portends for the future appeared first on Smithsonian Insider.

The move enhances coordination efforts for the 46-plot research network, which partners with more than 75 institutions in 21 countries.

The post Global forest science research center moves from Harvard to the National Museum of Natural History, Washington, D.C. appeared first on Smithsonian Insider.

They’ve got no roots or veins and grow in hanging pendants or tightly packed mats attached to stones, soil and wood. Called by some “the […]

The post Mosses have strong potential to acclimate to global warming, study indicates appeared first on Smithsonian Insider.

A 57-acre research plot at a University of Michigan forest preserve northwest of Ann Arbor has been added to a Smithsonian Institution global network used […]

The post University of Michigan forest preserve joins Smithsonian global network appeared first on Smithsonian Insider.

This year’s El Niño event is one of the strongest on record and is still ramping up. Large parts of the tropics are turning into […]

The post Major El Nino Perfect opportunity for Global Change Research appeared first on Smithsonian Insider.

The post Global forest network cracks the case of tropical biodiversity appeared first on Smithsonian Insider.

The Open Banking Report 2019 clarifies the role of key key-players in a post-September 14th world and assesses how the landscape has shifted within Europe and beyond.

Individual white paper containing all the latest updates to the Open Banking Global State of Play. Research conducted by The Paypers and Innopay

(The Paypers) HID Global, an identity solutions company, has completed the acquisition of the...

Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

The Paypers and Netherlands-based financial consultancy firm Innopay have released a

The Council of the National Academy of Sciences (NAS) is concerned about the confusion caused by a petition being circulated via a letter from a former president of this Academy.

Infectious disease outbreaks that turn into epidemics or pandemics can kill millions of people and cause trillions of dollars of damage to economic activity, says a new report from the international, independent Commission on a Global Health Risk Framework for the Future.

To make the world safer against future infectious disease threats, national health systems should be strengthened, the World Health Organization’s emergency and outbreak response activities should be consolidated and bolstered, and research and development should be enhanced, says a new Policy Forum article that appears in the May 19 edition of PLOS Medicine.

The U.S. Agency for International Development should speed its transformation into a global leader and catalyst in applying science, technology and innovation to the challenges facing developing countries, says a new report from the National Academies of Sciences, Engineering, and Medicine.

The U.S. Global Change Research Program (USGCRP) has made significant accomplishments to advance the science of global environmental change and improve the understanding of its impact on society through activities such as developing Earth-observing systems, improving Earth-system modeling capabilities, and advancing understanding of carbon-cycle processes, says a new report from the National Academies of Sciences, Engineering, and Medicine.

At the Science20 Dialogue Forum held today at the German National Academy of Sciences Leopoldina, a statement on improving global health was handed to German Chancellor Angela Merkel by representatives of the G20 science academies.

A new report from the National Academies of Sciences, Engineering, and Medicine identifies global health priorities in light of current and emerging challenges and makes 14 recommendations for the U.S. government and other stakeholders to address these challenges, while maintaining U.S. status as a world leader in global health.

NASA’s large strategic missions like the Hubble Space Telescope, the Curiosity rover on Mars, and the Terra Earth observation satellite are essential to maintaining the United States’ global leadership in space exploration and should continue to be a primary component of a balanced space science program that includes large, medium, and smaller missions, says a new report by the National Academies of Sciences, Engineering, and Medicine.

The U.S. National Academy of Sciences and U.S. National Academy of Medicine joined the science academies of South Africa, Brazil, and Germany today in issuing a statement calling for urgent worldwide action to reduce air pollution.

International thought leaders will join the next generation of engineers in London from Sept. 16 to 18 for the Global Grand Challenges Summit 2019. The summit aims to help inspire and equip future engineering leaders to address the rapidly evolving challenges of an unpredictable world.

A new study has investigated the impacts of human activity on Antarctic Marine and Coastal. Alongside local effects of fishing, pollution and invasive alien species, global climate change is causing sea temperature rises and ocean acidification. Action is therefore needed at all levels to address these impacts.

If we can’t secure the supply chain, eventually everything else will break

The post What happens when the global supply chain breaks? appeared first on WeLiveSecurity

While in France, a citizen of Brazil who resides in California books a bungee jump in New Zealand. Is it a leap of faith into the unknown, for both the operator and the thrill-seeker?

The post Is “global privacy” an oxymoron? appeared first on WeLiveSecurity

Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

Global air quality will significantly deteriorate by 2050 unless further steps are taken to cut current emissions from human activities, according to recent research. Most people around the world will be affected by worsening air quality with hotspots of particularly poor air occurring in China, northern India and the Middle East.

A recent study has revealed how water use has changed across the world over the last 60 years. Growing populations and economic development, particularly in newly-emerging countries, have increased water demand, but technological developments have led to water efficiencies and savings, which moderate these demands.